On March 27, the FDA permitted the marketing of the Dexcom G6 integrated continuous glucose monitoring system for diabetes patients aged 2 and older. Like most continuous glucose monitoring systems, Dexcom’s device contains a small sensor that monitors a patient’s blood glucose level and transmits real-time glucose readings to a compatible mobile device.
However, Dexcom’s device is also one of the first continuous glucose monitoring systems to work with other medical devices, including automated insulin dosing systems, insulin pumps and blood glucose meters.
“[T]he agency appears to be getting comfortable with what it takes to make an interoperable claim,” Bradley Merrill Thompson, a digital health expert and lawyer at Epstein, Becker and Green, told the Politico Morning eHealth newsletter. “I can’t recall FDA using the word ‘interoperable’ in an approval or clearance, but perhaps they have.”
More articles on supply chain:
FDA OKs first fully interoperable glucose monitoring system: 4 things to know
Amgen’s leukemia drug OK’d for patients in early remission
FDA to expand digital health pre-cert program by end of 2018: 3 things to know
